SpringWorks started at outperform by Evercore ahead of FDA decision

peterschreiber.media Evercore ISI has started coverage of SpringWorks Therapeutics ( NASDAQ: SWTX ) with an outperform rating, citing potential approval for its drug mirdametinib. The investment firm said it sees SpringWorks ( SWTX ) as well positioned due to its drug Ogsiveo for desmoid tumors.